We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

93 hedge funds and large institutions have $283M invested in BioXcel Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $4.8M | Put options by funds: $2.88M

57% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 23

0.25% more ownership

Funds ownership: 2.86% → 3.11% (+0.25%)

10% less funds holding

Funds holding: 103 → 93 (-10)

27% less capital invested

Capital invested by funds: $388M → $283M (-$105M)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

Holders
93
Holders Change
-10
Holders Change %
-9.71%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
36
Reduced
23
Closed
24
Calls
$4.8M
Puts
$2.88M
Net Calls
+$1.92M
Net Calls Change
+$2.22M

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$13.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$11M
3
Morgan Stanley
Morgan Stanley
New York
+$3.06M
4
Bank of America
Bank of America
North Carolina
+$2.07M
5
BlackRock
BlackRock
New York
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$1.8M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.65M
3
B
Bailard
California
-$1.4M
4
ACM
ACT Capital Management
Pennsylvania
-$805K
5
AS
Altshuler Shaham
Israel
-$744K
Name Holding Trade Value Shares
Change 		Change in
Stake
HWAM
26
Hennion & Walsh Asset Management
New Jersey
$701K +$57.5K +134 +7%
Two Sigma Investments
27
Two Sigma Investments
New York
$668K -$493K -1,148 -36%
AA
28
ALPS Advisors
Colorado
$658K -$51.1K -119 -6%
CL
29
CSS LLC
Illinois
$637K +$150K +350 +22%
WMSA
30
Weiss Multi-Strategy Advisers
New York
$609K -$3K -7 -0.4%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$592K +$781K +1,819 New
Deutsche Bank
32
Deutsche Bank
Germany
$582K -$115K -267 -13%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$526K +$17.6K +41 +3%
Wellington Management Group
34
Wellington Management Group
Massachusetts
$501K +$661K +1,540 New
Jane Street
35
Jane Street
New York
$476K +$356K +830 +131%
Barclays
36
Barclays
United Kingdom
$426K +$284K +662 +102%
ACM
37
ACT Capital Management
Pennsylvania
$407K -$805K -1,875 -60%
KCM
38
Knoll Capital Management
Florida
$407K – – –
Wells Fargo
39
Wells Fargo
California
$400K +$266K +619 +101%
Millennium Management
40
Millennium Management
New York
$391K +$516K +1,203 New
TAM
41
Tocqueville Asset Management
New York
$354K -$21.5K -50 -4%
HHAM
42
HITE Hedge Asset Management
Massachusetts
$333K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$327K +$21K +49 +5%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$307K – – –
CF
45
CNA Financial
Illinois
$292K +$115K +267 +42%
CIAS
46
Capital Investment Advisory Services
North Carolina
$286K -$56.2K -131 -13%
UBS AM
47
UBS AM
Illinois
$279K -$209K -488 -36%
CS
48
Credit Suisse
Switzerland
$276K +$1.72K +4 +0.5%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$266K +$63.5K +148 +22%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$262K -$654K -1,525 -65%
1
2
3 4 5

BTAI Hedge Fund Activity: Q4 2021 in Review

93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2021, worth a combined $283M — down 27% from $388M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of BTAI and 15 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 36 added.

The largest buyer was AllianceBernstein, adding an estimated $13.1M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $1.8M sold.

  • 93 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2021, down from 103 in Q3 2021.
  • Funds reported $283M of BioXcel Therapeutics stock for Q4 2021, down 27% quarter-over-quarter.
  • 15 funds opened new BioXcel Therapeutics positions in Q4 2021 and 24 closed out, a net change of -9 holders.
  • The largest BioXcel Therapeutics buyer in Q4 2021 was AllianceBernstein, an estimated $13.1M added.
  • The largest BioXcel Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $1.8M sold.

Based on aggregated 13F filings for Q4 2021.